Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

GPR50-Ctail cleavage and nuclear translocation: a new signal transduction mode for G protein-coupled receptors.

Ahmad R, Lahuna O, Sidibe A, Daulat A, Zhang Q, Luka M, Guillaume JL, Gallet S, Guillonneau F, Hamroune J, Polo S, Prévot V, Delagrange P, Dam J, Jockers R.

Cell Mol Life Sci. 2020 Jan 3. doi: 10.1007/s00018-019-03440-7. [Epub ahead of print]

PMID:
31900622
2.

Quantitative assessment of oligomeric amyloid β peptide binding to α7 nicotinic receptor.

Cecon E, Dam J, Luka M, Gautier C, Chollet AM, Delagrange P, Danober L, Jockers R.

Br J Pharmacol. 2019 Sep;176(18):3475-3488. doi: 10.1111/bph.14688. Epub 2019 May 20.

PMID:
30981214
3.

Detection of recombinant and endogenous mouse melatonin receptors by monoclonal antibodies targeting the C-terminal domain.

Cecon E, Ivanova A, Luka M, Gbahou F, Friederich A, Guillaume JL, Keller P, Knoch K, Ahmad R, Delagrange P, Solimena M, Jockers R.

J Pineal Res. 2019 Mar;66(2):e12540. doi: 10.1111/jpi.12540. Epub 2019 Jan 17.

PMID:
30475390
4.

Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure.

Benleulmi-Chaachoua A, Hegron A, Le Boulch M, Karamitri A, Wierzbicka M, Wong V, Stagljar I, Delagrange P, Ahmad R, Jockers R.

Cell Mol Life Sci. 2018 Dec;75(23):4357-4370. doi: 10.1007/s00018-018-2876-y. Epub 2018 Jul 24.

PMID:
30043140
5.

Hamster Melatonin Receptors: Cloning and Binding Characterization of MT₁ and Attempt to Clone MT₂.

Gautier C, Dufour E, Dupré C, Lizzo G, Caignard S, Riest-Fery I, Brasseur C, Legros C, Delagrange P, Nosjean O, Simonneaux V, Boutin JA, Guenin SP.

Int J Mol Sci. 2018 Jul 4;19(7). pii: E1957. doi: 10.3390/ijms19071957.

6.

First evidence of neuronal connections between specific parts of the periaqueductal gray (PAG) and the rest of the brain in sheep: placing the sheep PAG in the circuit of emotion.

Menant O, Prima MC, Morisse M, Cornilleau F, Moussu C, Gautier A, Blanchon H, Meurisse M, Delagrange P, Tillet Y, Chaillou E.

Brain Struct Funct. 2018 Sep;223(7):3297-3316. doi: 10.1007/s00429-018-1689-y. Epub 2018 Jun 4.

PMID:
29869133
7.

Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands.

Rivara S, Scalvini L, Lodola A, Mor M, Caignard DH, Delagrange P, Collina S, Lucini V, Scaglione F, Furiassi L, Mari M, Lucarini S, Bedini A, Spadoni G.

J Med Chem. 2018 Apr 26;61(8):3726-3737. doi: 10.1021/acs.jmedchem.8b00359. Epub 2018 Apr 4.

PMID:
29595267
8.

The orphan GPR50 receptor promotes constitutive TGFβ receptor signaling and protects against cancer development.

Wojciech S, Ahmad R, Belaid-Choucair Z, Journé AS, Gallet S, Dam J, Daulat A, Ndiaye-Lobry D, Lahuna O, Karamitri A, Guillaume JL, Do Cruzeiro M, Guillonneau F, Saade A, Clément N, Courivaud T, Kaabi N, Tadagaki K, Delagrange P, Prévot V, Hermine O, Prunier C, Jockers R.

Nat Commun. 2018 Mar 23;9(1):1216. doi: 10.1038/s41467-018-03609-x.

9.

Synthesis and biological evaluation of new naphtho- and quinolinocyclopentane derivatives as potent melatoninergic (MT1/MT2) and serotoninergic (5-HT2C) dual ligands.

Duroux R, Rami M, Landagaray E, Ettaoussi M, Caignard DH, Delagrange P, Melnyk P, Yous S.

Eur J Med Chem. 2017 Dec 1;141:552-566. doi: 10.1016/j.ejmech.2017.10.025. Epub 2017 Oct 12.

PMID:
29102176
10.

Importance of the second extracellular loop for melatonin MT1 receptor function and absence of melatonin binding in GPR50.

Clement N, Renault N, Guillaume JL, Cecon E, Journé AS, Laurent X, Tadagaki K, Cogé F, Gohier A, Delagrange P, Chavatte P, Jockers R.

Br J Pharmacol. 2018 Aug;175(16):3281-3297. doi: 10.1111/bph.14029. Epub 2017 Oct 27.

11.

New MT₂ Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists.

Boutin JA, Bonnaud A, Brasseur C, Bruno O, Lepretre N, Oosting P, Coumailleau S, Delagrange P, Nosjean O, Legros C.

Int J Mol Sci. 2017 Jun 23;18(7). pii: E1347. doi: 10.3390/ijms18071347.

12.

Design and validation of the first cell-impermeant melatonin receptor agonist.

Gbahou F, Cecon E, Viault G, Gerbier R, Jean-Alphonse F, Karamitri A, Guillaumet G, Delagrange P, Friedlander RM, Vilardaga JP, Suzenet F, Jockers R.

Br J Pharmacol. 2017 Jul;174(14):2409-2421. doi: 10.1111/bph.13856. Epub 2017 Jun 11.

13.

New quinolinic derivatives as melatonergic ligands: Synthesis and pharmacological evaluation.

Landagaray E, Ettaoussi M, Rami M, Boutin JA, Caignard DH, Delagrange P, Melnyk P, Berthelot P, Yous S.

Eur J Med Chem. 2017 Feb 15;127:621-631. doi: 10.1016/j.ejmech.2016.12.013. Epub 2017 Jan 3.

PMID:
28131094
14.

Update on melatonin receptors: IUPHAR Review 20.

Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, Cecon E, Zlotos DP.

Br J Pharmacol. 2016 Sep;173(18):2702-25. doi: 10.1111/bph.13536. Epub 2016 Aug 8. Review.

15.

Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.

Landagaray E, Ettaoussi M, Duroux R, Boutin JA, Caignard DH, Delagrange P, Melnyk P, Berthelot P, Yous S.

Eur J Med Chem. 2016 Feb 15;109:360-70. doi: 10.1016/j.ejmech.2015.12.047. Epub 2015 Dec 29.

PMID:
26820449
16.

Synthesis of 2-arylfuro[3,2-b]pyridines: Effect of the C2-aryl group on melatoninergic activity.

Couhert A, Delagrange P, Caignard DH, Chartier A, Suzenet F, Guillaumet G.

Eur J Med Chem. 2016 Feb 15;109:268-75. doi: 10.1016/j.ejmech.2016.01.008. Epub 2016 Jan 12.

PMID:
26785296
17.

Alternative Radioligands for Investigating the Molecular Pharmacology of Melatonin Receptors.

Legros C, Brasseur C, Delagrange P, Ducrot P, Nosjean O, Boutin JA.

J Pharmacol Exp Ther. 2016 Mar;356(3):681-92. doi: 10.1124/jpet.115.229989. Epub 2016 Jan 12.

PMID:
26759496
18.

Protein interactome mining defines melatonin MT1 receptors as integral component of presynaptic protein complexes of neurons.

Benleulmi-Chaachoua A, Chen L, Sokolina K, Wong V, Jurisica I, Emerit MB, Darmon M, Espin A, Stagljar I, Tafelmeyer P, Zamponi GW, Delagrange P, Maurice P, Jockers R.

J Pineal Res. 2016 Jan;60(1):95-108. doi: 10.1111/jpi.12294. Epub 2015 Nov 30.

PMID:
26514267
19.

Highly Potent and Selective MT2 Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines.

Spadoni G, Bedini A, Lucarini S, Mari M, Caignard DH, Boutin JA, Delagrange P, Lucini V, Scaglione F, Lodola A, Zanardi F, Pala D, Mor M, Rivara S.

J Med Chem. 2015 Sep 24;58(18):7512-25. doi: 10.1021/acs.jmedchem.5b01066.

PMID:
26334942
20.

Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers.

Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M, Chen P, Kalbasi Anaraki D, Baroncini M, Mannoury la Cour C, Millan MJ, Prevot V, Delagrange P, Jockers R.

J Biol Chem. 2015 May 1;290(18):11537-46. doi: 10.1074/jbc.M114.559542. Epub 2015 Mar 13.

21.

Acute tianeptine treatment selectively modulates neuronal activation in the central nucleus of the amygdala and attenuates fear extinction.

Godsil BP, Bontempi B, Mailliet F, Delagrange P, Spedding M, Jay TM.

Mol Psychiatry. 2015 Nov;20(11):1420-7. doi: 10.1038/mp.2014.169. Epub 2015 Jan 6.

PMID:
25560759
22.

Synthesis and pharmacological evaluation of dual ligands for melatonin (MT1/MT2) and serotonin 5-HT2C receptor subtypes (II).

Ettaoussi M, Pérès B, Errazani A, Boutin JA, Caignard DH, Delagrange P, Melnyk P, Berthelot P, Yous S.

Eur J Med Chem. 2015 Jan 27;90:822-33. doi: 10.1016/j.ejmech.2014.12.021. Epub 2014 Dec 13.

PMID:
25528336
23.

Intrinsic and extrinsic cues regulate the daily profile of mouse lateral habenula neuronal activity.

Sakhi K, Wegner S, Belle MD, Howarth M, Delagrange P, Brown TM, Piggins HD.

J Physiol. 2014 Nov 15;592(22):5025-45. doi: 10.1113/jphysiol.2014.280065. Epub 2014 Sep 5.

24.

Recombinant human melatonin receptor MT1 isolated in mixed detergents shows pharmacology similar to that in mammalian cell membranes.

Logez C, Berger S, Legros C, Banères JL, Cohen W, Delagrange P, Nosjean O, Boutin JA, Ferry G, Simonin F, Wagner R.

PLoS One. 2014 Jun 24;9(6):e100616. doi: 10.1371/journal.pone.0100616. eCollection 2014.

25.

Original Design of Fluorescent Ligands by Fusing BODIPY and Melatonin Neurohormone.

Thireau J, Marteaux J, Delagrange P, Lefoulon F, Dufourny L, Guillaumet G, Suzenet F.

ACS Med Chem Lett. 2013 Nov 20;5(2):158-61. doi: 10.1021/ml4004155. eCollection 2014 Feb 13.

26.

Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E.

Br J Pharmacol. 2014 Aug;171(15):3604-19. doi: 10.1111/bph.12720. Review.

27.

Agomelatine restores a physiological response to stress in the aged rat.

Descamps A, Rousset C, Dugua H, Debilly G, Delagrange P, Cespuglio R.

Neurosci Lett. 2014 Apr 30;566:257-62. doi: 10.1016/j.neulet.2014.02.044. Epub 2014 Mar 3.

PMID:
24602983
28.

New melatonin (MT1/MT2) ligands: design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives.

Landagaray E, Ettaoussi M, Leclerc V, Traoré B, Perez V, Nosjean O, Boutin JA, Caignard DH, Delagrange P, Berthelot P, Yous S.

Bioorg Med Chem. 2014 Feb 1;22(3):986-96. doi: 10.1016/j.bmc.2013.12.054. Epub 2014 Jan 3.

PMID:
24417958
29.

Daily variation in the electrophysiological activity of mouse medial habenula neurones.

Sakhi K, Belle MD, Gossan N, Delagrange P, Piggins HD.

J Physiol. 2014 Feb 15;592(4):587-603. doi: 10.1113/jphysiol.2013.263319. Epub 2013 Nov 18.

30.

Melatonin MT₁ and MT₂ receptors display different molecular pharmacologies only in the G-protein coupled state.

Legros C, Devavry S, Caignard S, Tessier C, Delagrange P, Ouvry C, Boutin JA, Nosjean O.

Br J Pharmacol. 2014 Jan;171(1):186-201. doi: 10.1111/bph.12457.

31.

Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT1 /MT2 agonist and 5-HT2C antagonist.

Ettaoussi M, Sabaouni A, Pérès B, Landagaray E, Nosjean O, Boutin JA, Caignard DH, Delagrange P, Berthelot P, Yous S.

ChemMedChem. 2013 Nov;8(11):1830-45. doi: 10.1002/cmdc.201300294. Epub 2013 Sep 12.

PMID:
24031039
32.

New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors.

Legros C, Matthey U, Grelak T, Pedragona-Moreau S, Hassler W, Yous S, Thomas E, Suzenet F, Folleas B, Lefoulon F, Berthelot P, Caignard DH, Guillaumet G, Delagrange P, Brayer JL, Nosjean O, Boutin JA.

Int J Mol Sci. 2013 Apr 25;14(5):8948-62. doi: 10.3390/ijms14058948.

33.

Rapid effects of melatonin on hormonal and behavioral stressful responses in ewes.

Guesdon V, Malpaux B, Delagrange P, Spedding M, Cornilleau F, Chesneau D, Haller J, Chaillou E.

Psychoneuroendocrinology. 2013 Aug;38(8):1426-34. doi: 10.1016/j.psyneuen.2012.12.011. Epub 2013 Jan 20.

PMID:
23337408
34.

Synthesis of new N-(arylcyclopropyl)acetamides and N-(arylvinyl)acetamides as conformationally-restricted ligands for melatonin receptors.

Morellato L, Lefas-Le Gall M, Langlois M, Caignard DH, Renard P, Delagrange P, Mathé-Allainmat M.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):430-4. doi: 10.1016/j.bmcl.2012.11.069. Epub 2012 Nov 29.

PMID:
23265885
35.

Novel conformationally constrained analogues of agomelatine as new melatoninergic ligands.

Rami M, Landagaray E, Ettaoussi M, Boukhalfa K, Caignard DH, Delagrange P, Berthelot P, Yous S.

Molecules. 2012 Dec 24;18(1):154-66. doi: 10.3390/molecules18010154.

36.

Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule.

Zhang H, Etherington LA, Hafner AS, Belelli D, Coussen F, Delagrange P, Chaouloff F, Spedding M, Lambert JJ, Choquet D, Groc L.

Mol Psychiatry. 2013 Apr;18(4):471-84. doi: 10.1038/mp.2012.80. Epub 2012 Jun 26.

37.

New quinoxaline derivatives as potential MT₁ and MT₂ receptor ligands.

Ancizu S, Castrillo N, Pérez-Silanes S, Aldana I, Monge A, Delagrange P, Caignard DH, Galiano S.

Molecules. 2012 Jun 25;17(7):7737-57. doi: 10.3390/molecules17077737.

38.

Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.

Venzala E, García-García AL, Elizalde N, Delagrange P, Tordera RM.

Psychopharmacology (Berl). 2012 Nov;224(2):313-25. doi: 10.1007/s00213-012-2754-5. Epub 2012 Jun 16.

PMID:
22707231
39.

Neuroanatomical distribution of the orphan GPR50 receptor in adult sheep and rodent brains.

Batailler M, Mullier A, Sidibe A, Delagrange P, Prévot V, Jockers R, Migaud M.

J Neuroendocrinol. 2012 May;24(5):798-808. doi: 10.1111/j.1365-2826.2012.02274.x.

PMID:
22512326
40.

Design, synthesis and pharmacological evaluation of new series of naphthalenic analogues as melatoninergic (MT1/MT2) and serotoninergic 5-HT2C dual ligands (I).

Ettaoussi M, Sabaouni A, Rami M, Boutin JA, Delagrange P, Renard P, Spedding M, Caignard DH, Berthelot P, Yous S.

Eur J Med Chem. 2012 Mar;49:310-23. doi: 10.1016/j.ejmech.2012.01.027. Epub 2012 Jan 20.

PMID:
22301214
41.

Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂.

Devavry S, Legros C, Brasseur C, Cohen W, Guenin SP, Delagrange P, Malpaux B, Ouvry C, Cogé F, Nosjean O, Boutin JA.

Eur J Pharmacol. 2012 Feb 29;677(1-3):15-21. doi: 10.1016/j.ejphar.2011.12.009. Epub 2011 Dec 20.

PMID:
22202844
42.

Description of the constitutive activity of cloned human melatonin receptors hMT(1) and hMT(2) and discovery of inverse agonists.

Devavry S, Legros C, Brasseur C, Delagrange P, Spadoni G, Cohen W, Malpaux B, Boutin JA, Nosjean O.

J Pineal Res. 2012 Aug;53(1):29-37. doi: 10.1111/j.1600-079X.2011.00968.x. Epub 2011 Oct 24.

PMID:
22017484
43.

Multiple exposures to familiar conspecific withdrawal is a novel robust stress paradigm in ewes.

Guesdon V, Ligout S, Delagrange P, Spedding M, Lévy F, Laine AL, Malpaux B, Chaillou E.

Physiol Behav. 2012 Jan 18;105(2):203-8. doi: 10.1016/j.physbeh.2011.08.011. Epub 2011 Aug 16.

PMID:
21871471
44.

Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands.

El Kazzouli S, Griffon du Bellay A, Berteina-Raboin S, Delagrange P, Caignard DH, Guillaumet G.

Eur J Med Chem. 2011 Sep;46(9):4252-7. doi: 10.1016/j.ejmech.2011.06.030. Epub 2011 Jul 1.

PMID:
21764185
45.

Insights into the redox cycle of human quinone reductase 2.

Reybier K, Perio P, Ferry G, Bouajila J, Delagrange P, Boutin JA, Nepveu F.

Free Radic Res. 2011 Oct;45(10):1184-95. doi: 10.3109/10715762.2011.605788. Epub 2011 Aug 9.

PMID:
21762045
46.

X-ray structural studies of quinone reductase 2 nanomolar range inhibitors.

Pegan SD, Sturdy M, Ferry G, Delagrange P, Boutin JA, Mesecar AD.

Protein Sci. 2011 Jul;20(7):1182-95. doi: 10.1002/pro.647. Epub 2011 May 23.

47.

Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindole derivatives as potent melatonin agonists.

Jeanty M, Suzenet F, Delagrange P, Nosjean O, Boutin JA, Caignard DH, Guillaumet G.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2316-9. doi: 10.1016/j.bmcl.2011.02.097. Epub 2011 Feb 26.

PMID:
21420861
48.

Preparation and pharmacological evaluation of a novel series of 2-(phenylthio)benzo[b]thiophenes as selective MT2 receptor ligands.

Mésangeau C, Fraise M, Delagrange P, Caignard DH, Boutin JA, Berthelot P, Yous S.

Eur J Med Chem. 2011 May;46(5):1835-40. doi: 10.1016/j.ejmech.2011.02.044. Epub 2011 Feb 23.

PMID:
21392858
49.

Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.

Leclerc V, Ettaoussi M, Rami M, Farce A, Boutin JA, Delagrange P, Caignard DH, Renard P, Berthelot P, Yous S.

Eur J Med Chem. 2011 May;46(5):1622-9. doi: 10.1016/j.ejmech.2011.02.010. Epub 2011 Feb 15.

PMID:
21377769
50.

Emotional memory impairments in a genetic rat model of depression: involvement of 5-HT/MEK/Arc signaling in restoration.

Eriksson TM, Delagrange P, Spedding M, Popoli M, Mathé AA, Ögren SO, Svenningsson P.

Mol Psychiatry. 2012 Feb;17(2):173-84. doi: 10.1038/mp.2010.131. Epub 2011 Jan 18.

Supplemental Content

Loading ...
Support Center